RAPID VIRAL CONTROL IN A WORLD THAT NEEDS IT

ExeVir is a clinical stage company developing single-domain antibody-based therapies that help patients ward off viral infections. Our lead candidate XVR011 is in accelerated development as a COVID-19 therapeutic.

TAKING THE LEAD IN THE FIGHT AGAINST COVID-19

COVID-19 is an unprecedented global threat, which requires a rapid and broad neutralising response due to its tremendous impact on patients, health care systems, societies and economies. We aim to bring antiviral treatments to help stop the pandemic in its tracks and to protect those most vulnerable.

XVR011, A POTENT, BROADLY NEUTRALISING SARS-COV-2 THERAPY

XVR011, our lead compound is a potent, broadly neutralising SARS-COV-2 antiviral treatment. XVR011, an enhanced version of VHH72-FC, binds to a highly conserved region on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell. It offers breadth and potency against a range of Sabecoviruses and is not impacted in its binding affinity to, or neutralising capacity of circulating SARS-CoV-2 Variants Of Concern.

VHH are single-domain antibody fragments derived from camelids, they are smaller than human antibodies and can attach to parts of a virus that are difficult to access for the human immune system. Stopping infection and viral replication supports the patient’s immune response by reducing the viral load and dampening local and systemic inflammation. This is particularly beneficial for those at increased risk of severe illness from COVID-19. 

XVR011, in clinical stage Phase 1b, is in accelerated development as a therapeutic and holds potential as a prophylactic to ringfence outbreaks.

XVR011 maintains in vitro neutralization activity against SARS-CoV-2 Variants of Concern, as well as the current Variants of Interest.

  • Based on its epitope sequence, no impact of any currently circulating Variant of Concern of Variant of Interest predicted
  • XVR011 demonstrated strong in vitro neutralization potency against the Variants of Concern Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Gamma (P.1). These data were generated in the laboratory of Professor Johan Neyts at the Rega institute (KU Leuven, Belgium)

EXEVIR'S RAPID VHH RESPONSE PLATFORM FOCUSED ON INFECTIOUS DISEASES

The concept of blocking viral replication using protein therapeutics built from camelid single domain antibody fragments is broadly applicable to a range of pathogens.

This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access.

Exevir is a growing company, building on its expertise to harness the platform capabilities in infectious diseases

ExeVir collaborates closely with the laboratories of Prof. Xavier Saelens and Prof. Nico Callewaert (VIB — Ghent University) to further develop new antiviral VHH antibodies.

CONTACT US

Do you have any questions about ExeVir’s technology, send us a message!